A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia

Trial Profile

A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs Uproleselan-sodium (Primary) ; Cytarabine; Etoposide; Idarubicin; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors GlycoMimetics
  • Most Recent Events

    • 27 Feb 2018 Status changed from active, no longer recruiting to completed, according to a GlycoMimetics media release.
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 According to a GlycoMimetics media release, data from this trial were presented at the 59th American Society of Hematology (ASH) Annual Meeting and Expo 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top